Investigation of the gut as a possible reservoir for the JC Polyoma virus in patients with multiple sclerosis under treatment with natalizumab
Recruiting
- Conditions
- A81.2Progressive multifocal leukoencephalopathy
- Registration Number
- DRKS00017542
- Lead Sponsor
- Biogen, Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
multiple sclerosis patients under treatment with natalizumab, signed form of consent
Exclusion Criteria
consent denied
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of the JCPyVirus in stool, blood and urine samples during treatment with natalizumab. When patients arrive in the clinic to receive their treatement, blood and urine samples will be obtained right away. In the days following the infusion a stool sample will be sent to the clinic by the patient.
- Secondary Outcome Measures
Name Time Method Quantitative and qualitative analysis of the Virus DNA in the stool, blood and urine samples.